Monitoring specific T-cell responses to melanoma vaccines: ELISPOT, tetramers, and beyond
- PMID: 10702484
- PMCID: PMC95840
- DOI: 10.1128/CDLI.7.2.141-144.2000
Monitoring specific T-cell responses to melanoma vaccines: ELISPOT, tetramers, and beyond
Similar articles
-
Enzyme-linked immunospot, cytokine flow cytometry, and tetramers in the detection of T-cell responses to a dendritic cell-based multipeptide vaccine in patients with melanoma.Clin Cancer Res. 2003 Feb;9(2):641-9. Clin Cancer Res. 2003. PMID: 12576430 Clinical Trial.
-
Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.Cancer J Sci Am. 1998 Sep-Oct;4(5):316-23. Cancer J Sci Am. 1998. PMID: 9815296 Clinical Trial.
-
Semi-allogeneic vaccines for patients with cancer and AIDS.J Immunother. 2002 Jul-Aug;25(4):334-41. doi: 10.1097/00002371-200207000-00005. J Immunother. 2002. PMID: 12142556
-
Melanoma vaccines: the paradox of T cell activation without clinical response.Cancer Chemother Pharmacol. 2000;46 Suppl:S62-6. doi: 10.1007/pl00014052. Cancer Chemother Pharmacol. 2000. PMID: 10950150 Review.
-
Melanoma vaccines.Hosp Med. 2004 Nov;65(11):668-73. doi: 10.12968/hosp.2004.65.11.17046. Hosp Med. 2004. PMID: 15566059 Review.
Cited by
-
Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan-Kynurenine-Aryl Hydrocarbon Axis.Clin Cancer Res. 2019 Mar 1;25(5):1462-1471. doi: 10.1158/1078-0432.CCR-18-2882. Epub 2018 Oct 30. Clin Cancer Res. 2019. PMID: 30377198 Free PMC article. Review.
-
Guidelines for the welfare and use of animals in cancer research.Br J Cancer. 2010 May 25;102(11):1555-77. doi: 10.1038/sj.bjc.6605642. Br J Cancer. 2010. PMID: 20502460 Free PMC article.
-
The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment.Semin Oncol. 2015 Aug;42(4):663-71. doi: 10.1053/j.seminoncol.2015.05.011. Epub 2015 Jun 3. Semin Oncol. 2015. PMID: 26320069 Free PMC article. Review.
-
MHC class II tetramer analyses in AE37-vaccinated prostate cancer patients reveal vaccine-specific polyfunctional and long-lasting CD4(+) T-cells.Oncoimmunology. 2016 May 2;5(7):e1178439. doi: 10.1080/2162402X.2016.1178439. eCollection 2016 Jul. Oncoimmunology. 2016. PMID: 27622033 Free PMC article.
-
Intensity of the vaccine-elicited immune response determines tumor clearance.J Immunol. 2002 Jan 1;168(1):338-47. doi: 10.4049/jimmunol.168.1.338. J Immunol. 2002. PMID: 11751979 Free PMC article.
References
-
- Altman J D, Moss P A H, Goulder P J R, Barouch D H, McHeyzer-Williams M G, Bell J I, McMichael A J, Davis M M. Phenotypic analysis of antigen-specific T lymphocytes. Science. 1996;274:94–96. - PubMed
-
- Anichini A, Molla A, Mortarini R, Tragni G, Bersani I, Di N M, Gianni A M, Pilotti S, Dunbar R, Cerundolo V, Parmiani G. An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions. J Exp Med. 1999;190:651–668. - PMC - PubMed
-
- Boon T, Cerottini J-C, Van den Eynde B, Van der Bruggen P, Van Pel A. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol. 1994;12:337–365. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical